Examples of Amgen Agreement in a sentence
Infinity hereby grants to JJPRD a worldwide, exclusive license (subject to the non-exclusive research and development license granted to Amgen under the Amgen Agreement), under Infinity Intellectual Property, to Develop products that contain Library Compounds and to [**] in Exclusive Library Compounds for any purposes.
Shionogi shall pay to directly to Amylin’s licensors (Rockefeller University and Amgen Inc.) the amounts of tiered royalty payments (the “Licensor Royalty Payments”) that Amylin owes to such licensors, pursuant to the Amgen Agreement and the Rockefeller License, based upon the sales of Licensed Products in the Territory.
Each of Amylin and Shionogi will promptly notify the other of any notice of default or breach that it receives from Amgen (or its successors or assigns) regarding the Amgen Agreement.
ZENYAKU acknowledges and agrees that the licenses granted by ANTHERA pursuant to Section 2.1 include sublicenses to Information and Patents that have been licensed to ANTHERA under the Amgen Agreement, and that such sublicenses are subject to the terms and conditions of the Amgen Agreement.
Amylin agrees to take all lawful steps reasonably necessary or requested by Shionogi to permit Shionogi to exercise and enforce Amylin’s rights under the Amgen Agreement to the extent of Shionogi’s rights under this Agreement.
Pursuant to the Amgen Agreement, the Company and Amgen will use the Company’s proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected.
Notwithstanding anything to the contrary in this Agreement, Shionogi agrees that the licenses and rights granted under this Agreement are subject to all terms, conditions and obligations under the Amgen Agreement.
Amylin shall have no liability to Shionogi for any termination or modification of the Amgen Agreement arising out of or resulting from the failure of Shionogi, its Affiliates and/or Sublicensees to abide by, comply with or perform under the terms, conditions or obligations of the Amgen Agreement.
Pursuant to the Amgen Agreement, the Company and Amgen use the Company’s proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected.
The decrease was primarily attributed to the recognition, during the third quarter of 2017, of $10.7 million of non-cash in-process research and development expense and $1.2 million of sublicense fee payable to the University of California, Santa Barbara, both as a result of the Amgen Agreement.